126 research outputs found
Lipopolysaccharide adsorbed to the bio-corona of TiO2 nanoparticles powerfully activates selected pro-inflammatory transduction pathways
An in vitro strategy to assess mitigation of hazardous properties of engineered metal nanoparticles
The huge progress in the nanotechnology field has requested the production of increasingly
advanced engineered nanoparticles (NPs). In particular, metal-based advanced NPs are
widely used in several industrial applications. However, their potential effects on human
health during occupational exposure are still incompletely characterized thus far and
possible strategies to decrease their hazardous properties are not yet clearly defined. In this
project we are developing an in vitro approach to test the cytotoxic effects of metal-based
NPs, as derived from production lines or modified through coating with organic or inorganic
moieties. We have used two cell models widely employed in toxicological studies, the human
alveolar cell line A549 and the murine macrophage cell line RAW264.7, to avoid possible
limitations due to cell specific effects. Moreover, in order to evaluate the effectiveness of
mitigation approaches for NPs endowed with little acute cytotoxicity, additional endpoints,
alternative to viability, have also been assessed. Colloidal suspensions of Ag, TiO2 and ZrO2
NPs were tested as provided by industries or modified with SiO2 NPs or citrate used as
coating remediation agents. Heterocoagulation of opposite charged phases was applied in
order to promote the coating of pristine surfaces by modifying agents. Heterocoagulated sols
were obtained by ball milling sols of positive charged Ag, TiO2 and ZrO2 NPs with negative
charged SiO2 NPs or citrate ions. Modified samples, obtained by spray-drying and re-
dispersing in water the corresponding sols, were also obtained in order to compare
reactivity. Original and modified NPs were added to culture media starting from water
colloidal suspensions. Viability was determined with the resazurin method in a range of
doses from 2.5 to 80 nfg/cm2 (0.3125 to 20 g/cm2 for Ag NPs) of monolayer surface at three
experimental times (24, 48 and 72h). The expression of the inducible form of nitric oxide
synthase (Nos2), an indicator of macrophage activation and, hence, of pro-inflammatory
activity, was assessed with RT-PCR as an end-point alternative to viability.
Among the NPs tested, only Ag NP caused a significant loss of viability, with an IC50 of about
0.8 g/cm2 for Raw264.7 cells and 2.4 g/cm2 for A549 cells at the 24h-experimental time. In
a preliminary experiment, SiO2 NPs were demonstrated to have no significant effect on cell
viability. The comparison between original and SiO2-coated Ag NPs, performed in the same
experiment, suggested a coating-independent mitigation effect of bioreactivity exerted by the
spray drying procedure. However, once corrected for the actual Ag content of the spray-
dried powder, no significant difference was found in the IC50 values, indicating that neither
silica coating nor spray drying mitigate cytotoxicity. The effects on viability of original TiO2
and ZrO2 NPs were assessed using P25 Aeroxide TiO2 NPs as a reference material. These
materials did not affect significantly cell viability at any time point tested, so that it was not
possible to estimate IC50 values for either cell line. However, titania produced a clear-cut
induction of Nos2 expression in Raw264.7 cells, thus indicating their potential pro-
inflammatory activity. Citrate coating did not produce any significant attenuation of the
biological effect. In summary, these preliminary results showed no mitigating effect of the
surface modifications tested on the biological effects of the engineered NPs investigated.
However, the exploitation of this in vitro experimental strategy can be useful for the
preliminary assessment of the mitigation potential of surface modifications of both low-toxic
and high-toxic engineered NPs.
Supported by EU Grant NMP4-SL-2012-280716 (Sanowork Project
Recommended from our members
Novel compound heterozygous pathogenic variants in nucleotide-binding protein like protein (NUBPL) cause leukoencephalopathy with multi-systemic involvement.
NUBPL (Nucleotide-binding protein like) protein encodes a member of the Mrp/NBP35 ATP-binding proteins family, deemed to be involved in mammalian complex I (CI) assembly process. Exome sequencing of a patient presenting with infantile-onset hepatopathy, renal tubular acidosis, developmental delay, short stature, leukoencephalopathy with minimal cerebellar involvement and multiple OXPHOS deficiencies revealed the presence of two novel pathogenic compound heterozygous variants in NUBPL (p.Phe242Leu/p.Leu104Pro). We investigated patient's and control immortalised fibroblasts and demonstrated that both the peripheral and the membrane arms of complex I are undetectable in mutant NUBPL cells, resulting in virtually absent CI holocomplex and loss of enzyme activity. In addition, complex III stability was moderately affected as well. Lentiviral-mediated expression of the wild-type NUBPL cDNA rescued both CI and CIII assembly defects, confirming the pathogenicity of the variants. In conclusion, this is the first report describing a complex multisystemic disorder due to NUBPL defect. In addition, we confirmed the role of NUBPL in Complex I assembly associated with secondary effect on Complex III stability and we demonstrated a defect of mtDNA-related translation which suggests a potential additional role of NUBPL in mtDNA expression
Titanium dioxide nanoparticles enhance macrophage activation by LPS through a TLR4-dependent intracellular pathway
Musculoskeletal Features without Ataxia Associated with a Novel de novo Mutation in KCNA1 Impairing the Voltage Sensitivity of Kv1.1 Channel
The KCNA1 gene encodes the subunit of the voltage-gated Kv1.1 potassium channel that critically regulates neuronal excitability in the central and peripheral nervous systems. Mutations in KCNA1 have been classically associated with episodic ataxia type 1 (EA1), a movement disorder triggered by physical and emotional stress. Additional features variably reported in recent years include epilepsy, myokymia, migraine, paroxysmal dyskinesia, hyperthermia, hypomagnesemia,
and cataplexy. Interestingly, a few individuals with neuromyotonia, either isolated or associated with skeletal deformities, have been reported carrying variants in the S2–S3 transmembrane segments of Kv1.1 channels in the absence of any other symptoms. Here, we have identified by whole-exome sequencing a novel de novo variant, T268K, in KCNA1 in a boy displaying recurrent episodes of neuromyotonia, muscle hypertrophy, and skeletal deformities. Through functional analysis in heterologous cells and structural modeling, we show that the mutation, located at the extracellular end of the S3 helix, causes deleterious effects, disrupting Kv1.1 function by altering the voltage dependence of activation and kinetics of deactivation, likely due to abnormal interactions with the voltage sensor in the S4 segment. Our study supports previous evidence suggesting that specific residues within the S2 and S3 segments of Kv1.1 result in a distinctive phenotype with predominant musculoskeletal presentation
Brain catecholamine depletion and motor impairment in a Th knock-in mouse with type B tyrosine hydroxylase deficiency
Tyrosine hydroxylase catalyses the hydroxylation of L-tyrosine to l-DOPA, the rate- limiting step in the synthesis of catecholamines. Mutations in the TH gene encoding tyrosine hydroxylase are associated with the autosomal recessive disorder tyrosine hydroxylase deficiency, which manifests phenotypes varying from infantile parkinsonism and DOPA-responsive dystonia, also termed type A, to complex encephalopathy with perinatal onset, termed type B. We generated homozygous Th knock-in mice with the mutation Th-p.R203H, equivalent to the most recurrent human mutation associated with type B tyrosine hydroxylase deficiency (TH-p.R233H), often unresponsive to l-DOPA treatment. The Th knock-in mice showed normal survival and food intake, but hypotension, hypokinesia, reduced motor coordination, wide-based gate and catalepsy. This phenotype was associated with a gradual loss of central catecholamines and the serious manifestations of motor impairment presented diurnal fluctuation but did not improve with standard l-DOPA treatment. The mutant tyrosine hydroxylase enzyme was unstable and exhibited deficient stabilization by catecholamines, leading to decline of brain tyrosine hydroxylase-immunoreactivity in the Th knock-in mice. In fact the substantia nigra presented an almost normal level of mutant tyrosine hydroxylase protein but distinct absence of the enzyme was observed in the striatum, indicating a mutation-associated mislocalization of tyrosine hydroxylase in the nigrostriatal pathway. This hypomorphic mouse model thus provides understanding on pathomechanisms in type B tyrosine hydroxylase deficiency and a platform for the evaluation of novel therapeutics for movement disorders with loss of dopaminergic input to the striatum
Anxiety and depression in Charcot-Marie-Tooth disease: data from the Italian CMT national registry
Background There is little information about neuropsychiatric comorbidities in Charcot-Marie-Tooth disease (CMT). We assessed frequency of anxiety, depression, and general distress in CMT.Methods We administered online the Hospital Anxiety-Depression Scale (HADS) to CMT patients of the Italian registry and controls. HADS-A and HADS-D scores >= 11 defined the presence of anxiety/depression and HADS total score (HADS-T) >= 22 of general distress. We analysed correlation with disease severity and clinical characteristics, use of anxiolytics/antidepressants and analgesic/anti-inflammatory drugs.Results We collected data from 252 CMT patients (137 females) and 56 controls. CMT patient scores for anxiety (mean +/- standard deviation, 6.7 +/- 4.8), depression (4.5 +/- 4.0), and general distress (11.5 +/- 8.1) did not differ from controls and the Italian population. However, compared to controls, the percentages of subjects with depression (10% vs 2%) and general distress (14% vs 4%) were significantly higher in CMT patients. We found no association between HADS scores and disease duration or CMT type. Patients with general distress showed more severe disease and higher rate of positive sensory symptoms. Depressed patients also had more severe disease. Nineteen percent of CMT patients took antidepressants/anxiolytics (12% daily) and 70% analgesic/anti-inflammatory drugs. Patients with anxiety, depression, and distress reported higher consumption of anxiolytics/antidepressants. About 50% of patients with depression and/or general distress did not receive any specific pharmacological treatment.Conclusions An appreciable proportion of CMT patients shows general distress and depression. Both correlated with disease severity and consumption of antidepressants/anxiolytics, suggesting that the disease itself is contributing to general distress and depression
Correction of a urea cycle defect after ex vivo gene editing of human hepatocytes
Ornithine transcarbamylase deficiency (OTCD) is a monogenic disease of ammonia metabolism in hepatocytes. Severe disease is frequently treated by orthotopic liver transplantation. An attractive approach is the correction of a patient's own cells to regenerate the liver with gene-repaired hepatocytes. This study investigates the efficacy and safety of ex vivo correction of primary human hepatocytes. Hepatocytes isolated from an OTCD patient were genetically corrected ex vivo, through the deletion of a mutant intronic splicing site achieving editing efficiencies >60% and the restoration of the urea cycle in vitro. The corrected hepatocytes were transplanted into the liver of FRGN mice and repopulated to high levels (>80%). Animals transplanted and liver repopulated with genetically edited patient hepatocytes displayed normal ammonia, enhanced clearance of an ammonia challenge and OTC enzyme activity, as well as lower urinary orotic acid when compared to mice repopulated with unedited patient hepatocytes. Gene expression was shown to be similar between mice transplanted with unedited or edited patient hepatocytes. Finally, a genome-wide screening by performing CIRCLE-seq and deep sequencing of >70 potential off-targets revealed no unspecific editing. Overall analysis of disease phenotype, gene expression, and possible off-target editing indicated that the gene editing of a severe genetic liver disease was safe and effective.
Keywords: CRISPR; FRGN; ex vivo; genome editing; hepatocyte transplantation; liver-humanized mouse; primary hepatocytes; urea cycle disorder
Frequency, entity and determinants of fatigue in Charcot-Marie-Tooth disease
Fatigue, a disabling symptom in many neuromuscular disorders, has been reported also in Charcot-Marie-Tooth disease (CMT). The presence of fatigue and its correlations in CMT was investigated
- …